Australia markets closed

Alpha Teknova, Inc. (TKNO)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
1.7800+0.1000 (+5.95%)
At close: 04:00PM EDT
1.6900 -0.09 (-5.06%)
After hours: 07:05PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close1.6800
Open1.7300
Bid1.3400 x 200
Ask2.3200 x 200
Day's range1.6900 - 1.9200
52-week range1.6200 - 4.2700
Volume26,006
Avg. volume11,313
Market cap72.666M
Beta (5Y monthly)0.23
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Teknova to Report First Quarter 2024 Financial Results on May 13, 2024

    HOLLISTER, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the first quarter ended March 31, 2024, on Monday, May 13, 2024, following the close of market. Teknova will host a webcast and conference call on Monday, May 13, 2024, beginni

  • GlobeNewswire

    Teknova Reports Fourth Quarter and Full Year 2023 Financial Results

    Full year 2023 total revenue was $36.7 million, down 11% year-over-yearAchieved 36% annual growth in the number of Clinical Solutions customers in 2023Company provides 2024 revenue guidance of $35-38 million HOLLISTER, Calif., March 11, 2024 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova” or the “Company”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced financ

  • GlobeNewswire

    Teknova to Report Fourth Quarter and Full Year 2023 Financial Results on March 11, 2024

    HOLLISTER, Calif., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the fourth quarter and full year ended December 31, 2023, on Monday, March 11, 2024, following the close of market. Teknova will host a webcast and conference call on Monday, Ma